---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-030267"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:38:58.299930+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharmaceuticals prices $30M public offering; net proceeds ~$32.4M

## Summary
- Offering of 16,666,667 common shares at $1.50/share and 3,333,333 pre-funded warrants at $1.499/warrant.
- Underwriters' option for 3,000,000 additional common shares exercised in full.
- Net proceeds of ~$32.4M to fund etripamil development for PSVT and AFib-RVR, plus working capital.
- Expected to close on or about March 4, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001104659-24-030267
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/0001104659-24-030267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/tm247820d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-030267
- JSON: https://secwatch.observer/filing/0001104659-24-030267.json
- Plain text: https://secwatch.observer/filing/0001104659-24-030267.txt

## Key facts
- Material Agreements
  Milestone Pharmaceuticals Inc. entered into Underwriting Agreement with Piper Sandler & Co. as representative of the several underwriters (effective 2024-02-28).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co. as representative of the several underwriters
  - Effective: 2024-02-28
  source text: On February 28, 2024, Milestone Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 16,666,667 of the Company’s common shares, without par value (the “Common Shares”), at a public offering price of $1.50 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/0001104659-24-030267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.